Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
NEW YORK and PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building high-performing teams, developing innovative diagnostic tests, establishing world-class laboratory environments, and advancing critical research in cancer biology, genomics, and epigenetics.Dr. Shaknovich currently serves as Chief Medical Officer at Agilent Technologies, where she oversees medical strategy and contributes to the development of innovative diagnostic solutions. Prior to joining Agilent, Dr. Shaknovich held senior leadership positions at GRAIL and Cancer Genetics, where she played pivotal roles in clinical and translational initiatives. She began her career in academic medicine, serving as Assistant Professor at Weill Cornell Medical College and Montefiore Medical Center (NY).
"We are honored to welcome Dr. Shaknovich to our Scientific Advisory Board," said Dr. Patrizia Paterlini, CEO and Founder of Rarecells, Inc. "Her extensive expertise in molecular pathology and her commitment to advancing cancer diagnostics align perfectly with Rarecells' mission to revolutionize early cancer detection through innovative liquid biopsy technologies."
Rarecells, Inc. is renowned for its ISET® (Isolation by SizE of Tumor cells) technology, a cutting-edge approach that enables the detection of circulating tumor cells (CTCs) and CTC-DNA in the bloodstream, facilitating early cancer diagnosis and monitoring. The addition of Dr. Shaknovich to the Scientific Advisory Board underscores the company's dedication to integrating top-tier scientific insights into its research and development efforts.
"I am excited to join Rarecells' Scientific Advisory Board and contribute to their groundbreaking work in liquid biopsy," said Dr. Shaknovich. "Early detection is crucial in the fight against cancer, and I look forward to collaborating with the team to advance technologies that can significantly impact patient outcomes."
About Rarecells, Inc.
Rarecells, Inc. is a leading company in the development of innovative non-invasive tests for early cancer diagnosis based on the proprietary hypersensitive approaches of combined CTC-DNA, ctDNA molecular detection and AI-based Circulating Tumor Cells (CTCs) identification. Founded in 2012, the firm is headquartered in New York with offices and laboratories in New York and Paris.
For more information, visit www.rarecells.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6f3c244-7537-4d5c-9c2a-11f18a5f48b0
CONTACT: Contact: media@rarecells.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
4 hours ago
- New York Post
Dog's ashes among dozens to rocket into orbit this weekend
Bone voyage! A beloved dog named Franz will take his final leap this weekend — into Earth's orbit. The yellow labrador's ashes will be on board the inaugural Perseverance Flight from Texas-based Celestis Inc., which is scheduled to launch around 5:30 p.m. Sunday from Vandenberg Space Force Base in Santa Barbara, CA. 4 Franz was like a sibling to Elizabeth Moore before he died at age 13 in October 2020. Celestis, Inc Carrying a total of 166 titanium and aluminum capsules, each about a quarter to a half-inch in size and filled with DNA or cremated remains, the 23-foot-tall SpaceX Falcon 9 rocket will take two trips around Earth's low orbit at a mind-boggling 17,000 mph. The space flight will last about three hours before the rocket — still carrying its priceless payload — re-enters the atmosphere and lands in the Pacific Ocean somewhere between Alaska and Hawaii, according to Celestis CEO and co-founder Charles Chafer. A recovery ship, which was already out at sea Friday in anticipation of the launch, 'will track the incoming rocket, hopefully get a visual on it, and then go pick it up out of the ocean,' Chafer explained. 4 The Texas-based company Celestis Inc.'s inaugural Perseverance Flight will take two trips around Earth's Lower Orbit after blastoff on Sunday. The capsules will first be transported to Germany, then, within two months, distributed back to the families, who each paid a whopping $3,500 to send their loved one to the stars. While the price to send Franz on the voyage was 'a lot more' than the pooch itself, his owner, Harvin Moore, said with a laugh, it was only fitting for the 'space-fanatic' Moore family to send the pup beyond the stratosphere. 'He was the best dog, just so soft and nice and loved hugs,' recalled Moore, 60, who lives in Dripping Springs, Texas, just outside Austin. 4 The Moore family can't wait to watch their beloved pooch go galactic. Celestis, Inc Franz, who was 13 when he died in October 2020, was more like a sibling than a pet to Moore's now 26-year-old daughter, Elizabeth, and son, Quinn, 21, he said. Now, the family can't wait to watch the good boy go galactic. 'The emotional power of being with a group of people who are celebrating the life of a loved one in this way … it's amazing. It's nothing we'll ever forget,' said Moore. 'It's just pure joy.' 4 The Perseverance Flight will carry a total of 166 titanium and aluminum capsules, ranging in size from a quarter to a half-inch, filled with DNA or cremated remains. Celestis, Inc 'Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy,' Chafer said. The cremated remains of Wesley Dreyer — an aerospace engineer who helped investigate the cause of the Space Shuttle Challenger's shocking explosion after takeoff on Jan. 28, 1986 — will also be on board the Perseverance Flight, as well as DNA from a living, 3-year-old German boy.
Yahoo
7 hours ago
- Yahoo
How Local Economic Development Act funds help New Mexico businesses grow
NEW MEXICO (KRQE) – For years, state and city grant funding has been used to grow businesses in New Mexico with the goal of keeping jobs here and boosting the economy. One local business who has expanded over the years said it's all thanks to that local funding. Vitality Works, located in Albuquerque, makes dietary and herbal supplements. 'We are the guys that really make the stuff for over 600 brands in the United States. Our name is on nothing, but we make other people's goods and fully package turnkey operations,' said Vitality Works CEO/Founder Mitch Coven. Coven said since he started his company in the 1980's, it's far surpassed his goals. He said the growth wouldn't have been possible without money from grants and tax credits. 'Everything that the city, county, state has made available to us has helped foster our growth even faster,' added Coven. One of the grants he's received is through the Local Economic Development Act, or LEDA which was signed into New Mexico law in the early 90's to incentivize and support growing businesses. 'We want the public sector to be an enabling partner that allows those entrepreneurs and those companies to be successful,' said Director of Economic Development for the City of Albuquerque Max Gruner. Vitality Works is just one company that's benefited from LEDA in the metro. In just the past eight years, the city of Albuquerque has committed more than $13.7 million in LEDA funding to help grow and retain 15 businesses. Those who qualify are expected to show how their company will expand, create jobs and have a local economic impact. 'We are really trying to use the mechanism of these incentives to create generational wealth for our families in Albuquerque,' said Gruner. Vitality Works produces 50,000 bottles of supplements and more a day. Coven believes his company is a way to give back to New Mexico as he employs more than 300 people and he sources some herbs in the state. His company is receiving it's second LEDA funding, which he hopes to use to expand the company even further by adding another 30,000 square feet to his facility. 'Our plans are to keep capturing the growth. We have to keep expanding,' said Coven. State LEDA funds are appropriated by the legislature, while participating cities also have their own LEDA funds, which are controlled by city councils. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Is J.B. Hunt Transport Stock Underperforming the S&P 500?
Lowell, Arkansas-based J.B. Hunt Transport Services, Inc. (JBHT) provides surface transportation, delivery, and logistics services in the United States. With a market cap of $13.8 billion, the company operates through five segments: Intermodal (JBI), Dedicated Contract Services (DCS), Integrated Capacity Solutions (ICS), Final Mile Services (FMS), and Truckload (JBT). Companies worth $10 billion or more are typically referred to as "large-cap stocks." JBHT fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the integrated freight & logistics industry. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Despite its strengths, the stock has dipped 30.6% from its 52-week high of $200.40 touched on Nov. 11, 2024. Moreover, over the past three months, JBHT stock has declined 5.5%, underperforming the S&P 500 Index's ($SPX) 5.4% uptick during the same time frame. JBHT stock has declined 18.6% on a YTD basis, underperforming SPX's 1.7% uptick in 2025. Moreover, JBHT has declined 10.7% over the past 52 weeks, underperforming SPX's 9% gains. JBHT stock has been trading below its 200-day moving average since mid-February and mostly above its 50-day moving average since mid-May. On Apr. 15, JBHT stock declined 2% following the release of its Q1 earnings. The trucking and logistics company posted revenue of $2.92 billion in the period, which met Street forecasts. Moreover, its adjusted earnings for the quarter amounted to $1.17, surpassing the consensus estimates by 1.7%. Within the integrated freight & logistics industry, rival Expeditors International of Washington, Inc. (EXPD) has grown 2.1% in 2025 and has declined 9.2% over the past year, slightly outperforming the stock. Among the 24 analysts covering the JBHT stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $151.33 suggests a modest 8.9% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
